Results 141 to 150 of about 9,966,852 (260)
Future advances of artificial biosensor technology in biomedical applications
Talanta OpenRecent advancements in synthetic biology have facilitated the concept of a cell-based and cell-free biosensing platform, which enables the identification of molecular signals encompassing metal/chemical to disease biomarkers.
Smriti Gaba +3 more
doaj +1 more source
Molecular Oncology, EarlyView.This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska +13 more
wiley +1 more source
Mechanism-based and data-driven modeling in cell-free synthetic biology
Chemical CommunicationsThis highlight discusses state-of-the-art mechanism-based modeling and machine-learning approaches in cell-free synthetic biology and their potential for designing and optimizing novel genetic circuits.
Angelina Yurchenko +4 more
openaire +2 more sources
LDBT instead of DBTL: combining machine learning and rapid cell-free testing
Nature CommunicationsSynthetic biology is defined by Design-Build-Test-Learn cycles. Recent advances in machine learning are changing the landscape; thus, we propose that “Learning” can precede “Design”. Moreover, adopting cell-free platforms can further accelerate “Building”
Alia Clark-ElSayed +5 more
doaj +1 more source
Molecular Oncology, EarlyView.We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober +16 more
wiley +1 more source
Finding novel vulnerabilities of hypomorphic BRCA1 alleles
Molecular Oncology, EarlyView.Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder +10 more
wiley +1 more source
Nature CommunicationsCell-free protein expression (CFE) systems have emerged as a critical platform for synthetic biology research. The vectors for protein expression in CFE systems mainly rely on double-stranded DNA and single-stranded RNA for transcription and translation ...
Zhijin Tian +8 more
doaj +1 more source
Molecular Oncology, EarlyView.The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka +9 more
wiley +1 more source
The rise of bottom-up synthetic biology and cell-free biology [PDF]
Physical Biology, 2019 openaire +2 more sources
A T7 RNAP regulatory toolbox for cell-free network engineering and biosensing applications
Nature CommunicationsT7 RNA polymerase is ubiquitously used in the fields of synthetic biology and biotechnology. Yet the ability to precisely and modularly regulate T7 RNAP remains surprisingly limited.
Pao-Wan Lee +3 more
doaj +1 more source